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Abstract
Introduction. Many studies suggest that atrial fibrillation (AF) is associated with an increased risk of functional decline 
and may contribute to the development of dementia. It is not known whether the CHA2DS2-VASc scale allows the deve-
lopment of dementia in patients with AF to be predicted.
To assess whether CHA2DS2-VASc score can be a predictor of dementia evaluated with Mini-Mental State Examination 
(MMSE) questionnaire in the elderly patients with atrial fibrillation.
Material and methods. The study included 157 patients (mean age 73.4) with non-valvular atrial fibrillation and no 
history of stroke. The presence of dementia was defined as the MMSE score of ≤ 23 points.
Results. The univariate analysis revealed that age (b = 0.132, p < 0.001), heart failure (b = 0.786, p = 0.033) and 
CHA2DS2-VASc score were significant determinants of dementia. In multivariate analysis, the CHA2DS2-VASc score was 
proved to be an independent determinant of dementia (β = 0.385, p = 0.003). Prevalence of dementia was one and 
a half times higher in the group of patients with a CHA2DS2-VASc score > 4 points (odds ratio = 0.47) that in the group 
of patients with CHA2DS2-VASc score ≤ 4 points.
Conclusion. The CHA2DS2-VASc score is a useful predictor of dementia in the ageing population with atrial fibrillation 
without clinical stroke.
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Introduction
Atrial fibrillation (AF) is a common arrhythmia that constitu-
tes an independent risk factor for stroke and is associated 
with increased morbidity and mortality. AF prevalence 
rises with age and affects up to 9% of the population over 
80 years of age [1].
The ageing of the population also leads to an increa-
sed risk of cognitive impairment (CI) and dementia [2, 3].
Many studies suggest that AF is associated with an 
increased risk of CI and functional decline and may con-
tribute to the development of dementia [4]. CI is frequen-
tly associated with AF, although the relationship between 
them remains controversial, especially in the absence of 
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Instrument
We employed the MMSE developed by Folstein et al. [6]. 
This is a widely used screening test for dementia, whose 
advantages include the speed of administration and simple 
interpretation of its results. The MMSE measures cognitive 
function such as a sense of direction, memory, attention, 
linguistic function, and visual-spatial abilities, as well as 
the ability to count, recall things, repeat, and carry out 
orders. The possible score ranges from 0 to 30, with lower 
scores indicating more severe cognitive function disorders. 
Patients with scores ≤ 27 are described as cognitively 
impaired [6].
A CHA2DS2-VASc scale is a tool for assessing the risk of 
thromboembolic complications in patients with atrial fibril-
lation. The scale allows the identification of patients with AF 
who require antiplatelet or anticoagulant therapy. The risk 
assessment includes factors such as hypertension, old age 
(age 65 to 74 years or age 75 and older) diabetes mellitus, 
prior stroke or thromboembolic event, congestive heart fa-
ilure/LV dysfunction, vascular disease and female sex [1].
Statistical analysis
Statistical analysis of the results was performed with STA-
TISTICA v. 12 (StatSoft, Inc. Tulsa, USA). Quantitative data 
(age, CHA2DS2-VASc score) were presented as mean and 
standard deviations [mean (M) ± standard deviation (SD)]. 
Qualitative data (sex, concomitant diseases etc.) were 
shown in contingency tables in the form of size (N) and 
percentage (%). The independence of qualitative variables 
from dementia was verified using the chi-square test. The 
significance of differences between the mean values of 
quantitative variables in the two groups was verified with 
the t-test for independent variables. To assess the strength 
of the correlation between the MMSE score and CHA2DS2-
-VASc score the Spearman’s rank correlation coefficient 
was calculated. Receiver operator characteristic curve 
analysis was used to establish cut-off values for demen-
tia. The predictors of dementia (univariate analysis) were 
determined using simple logistic regression and stepwise 
multiple regression.
Results
The study involved 157 AF patients (including 77 women) 
aged M = 73.4; SD = 8.3. The mean CHA2DS2-VASc score 
achieved by the patients studied was 3.90 ± 1.46. The 
participants were categorized by the level of cognitive 
function. According to the MMSE results, patients were 
divided into three groups: without cognitive impairment 
(Group 1; MMSE ≥ 27), with cognitive impairment without 
stroke. It has been demonstrated that even among patients 
with AF without clinical stroke, the arrhythmia is still asso-
ciated with CI and dementia [5].
However, it is not known whether this scale allows 
the development of dementia in patients with AF to be 
predicted. How to predict dementia occurrence among 
AF patients is not clear. There is limited information abo-
ut the use of CHADS2 and CHA2DS2-VASc score to predict 
dementia
Material and methods
Aim of the study
To assess whether CHA2DS2-VASc score can be a predictor 
of dementia evaluated with Mini-Mental State Examination 
(MMSE) questionnaire in the elderly patients with atrial 
fibrillation.
Study design and sample
The study was conducted between January 2015 and 
September 2016 at the Cardiology Department. It involved 
164 patients consecutively admitted to the hospital and 
selected by the cardiologist based on the inclusion and 
exclusion criteria.
The inclusion criteria were age > 60 years, a diagnosis 
of atrial fibrillation (paroxysmal, persistent or permanent), 
and anticoagulant treatment lasting for at least six months. 
The exclusion criteria were previous ischemic stroke and 
a lack of consent to participate in the study. Ultimately, 
7 patients were excluded. The study involved 157 patients 
who were over 60 years of age, were diagnosed with AF and 
had used oral anticoagulant — either vitamin K antagonist 
(VKA) or a non-vitamin K oral anticoagulants (NOAC) — for 
at least six months. The questionnaires were distributed by 
a specialist cardiac nurse at discharge. All patients were 
informed of the purpose and nature of this study and pro-
vided their written informed consent to be included in it. 
Based on the MMSE questionnaire score, the study group 
was divided into the following groups [6]:
 — dementia (≤ 23 pts);
 — cognitive impairment without dementia (> 23 pts < 
< 27pts);
 — absence of cognitive impairment (≥ 27 pts).
Information concerning the sociodemographic and cli-
nical data come from the hospital registry files.
Ethical consideration
This study was approved by the Bioethical Committee. All 
qualified patients provided their informed and voluntary 
consent to participate in the study.
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dementia (Group 2; MMSE 24–26) and with dementia 
(Group 3; MMSE ≤ 23). The groups compared differed in 
terms of age: the patients in Group 3 were significantly 
older than those from Group 2 and Group 1 (the mean age 
in Group 3 was 78.9 ± 7.8, in Group 2 — 75.3 ± 6.6 and in 
Group 1 — 70.0 ± 6.9, p < 0.001). In addition, Group 3 had 
the largest percentage of patients aged > 75 (69.0% vs. 
64.3% vs. 31.5%, p < 0.001). Furthermore, a statistically 
significant difference in CHA2DS2-VASc score was observed 
among the groups. Group 3 achieved a result with higher 
statistical significance than the remaining two groups: 4.48 
± 1.49 Group 3 versus 4.19 ± 1.25 Group 2 versus 3.40 
± 1.40 Group 1; p < 0.001. Statistically significant differen-
ces between the studied groups and the occurrence of renal 
dysfunction were observed — Group 3 was characterized by 
the highest percentage of patients compared to the other 
groups (57.1 Group 3 vs. 47.6 Group 2 vs. 32.9 Group 1, 
p = 0.033). No statistically significant differences were 
found for the remaining factors included in the study: sex, 
components of the CHA2DS2-VASc scale, duration of atrial 
fibrillation, type of atrial fibrillation, type of anticoagulant 
treatment administered and coexisting hyperthyroidism, 
respiratory system diseases and rheumatic diseases. The 
results are presented in Table 1.
Table 1. Clinical characteristics of patient groups classified based on cognitive function
Attribute (variable) Group 1 










Age 70.0 ± 6.9 75.3 ± 6.6 78.9 ± 7.8 < 0.001
Age > 65 years 59 (80.8) 40 (95.2) 41 (97.6) 0.007
Age > 75 years 23 (31.5) 27 (64.3) 29 (69.0) < 0.001
Female sex 29 (39.7) 25 (59.5) 23 (54.8) 0.085
City inhabitant 58 (79.5) 31 (73.8) 35 (83.3) 0.558
Comorbidities
Hypertension 61 (83.6) 32 (76.2) 37 (88.1) 0.342
Diabetes mellitus 15 (20.6) 13 (31.0) 10 (23.8) 0.454
Heart failure 23 (31.5) 13 (31.0) 21 (50.0) 0.098
Ischaemic heart disease 8 (11.0) 6 (14.3) 10 (23.8) 0.179
Hyperthyroidism 10 (13.7) 3 (7.1) 5 (11.9) 0.566
Respiratory system diseases 7 (9.6) 2 (4.8) 5 (11.9) 0.498
Prior vascular diseases 14 (19.2) 9 (21.4) 12 (28.6) 0.501
Rheumatic diseases 9 (12.3) 6 (14.3) 6 (14.3) 0.937
Other diseases 24 (32.9) 20 (47.6) 24 (57.1) 0.033
Duration of atrial fibrillation
Up to 5 50 (68.5) 27 (64.3) 21 (50.0)
0.174
6 to 10 years 10 (13.7) 5 (11.9) 12 (28.6)
Over 10 years 13 (17.8) 10 (23.8) 9 (21.4)
Type of atrial fibrillation
Paroxysmal/persistent 34 (46.6) 21 (50.0) 14 (33.3) 0.253
Permanent 39 (53.4) 21 (50.0) 28 (66.7)
Anticoagulant therapy
VKA 60 (82.2) 34 (81.0) 33 (78.6) 0.893
NOAC 13 (17.8) 8 (19.0) 9 (21.4)
CHA2DS2-VASc score 3.40 ± 1.40 4.19 ± 1.25 4.48 ± 1.49 < 0.001
MMSE — Mini-Mental State Examination; VKA — vitamin K antagonist; NOAC — non-vitamin K oral anticoagulants
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Next, logistic regression analysis of predictors for 
dementia was conducted. Significant determinants of 
dementia in the univariate logistic regression analysis 
were: age (b = 0.132; p < 0.001) — especially among 
patients aged > 75 (b = 1.065; p = 0.006), heart failu-
re (b = 0.786; p = 0.033), other diseases (renal disfun-
ction) (b = 0,766, p = 0,036) and the CHA2DS2-VASc scale 
(b = 0.385; p = 0.003). The score on the CHA2DS2-VASc 
scale was found to be a significant independent determi-
nant of cognitive impairment with dementia in the multi-
variate logistic regression analysis (b = 0.385; p = 0.003). 
The results are presented in Table 2.
We found a statistically significant negative moderate 
correlation between the score on the MMSE scale and the 
risk of thromboembolic complications assessed with the 
CHA2DS2-VASc scale (rho = –0.343). The percentage of 
cognitive impairment points consequently increases with 
increase in the CHA2DS2-VASc scores (Figure 1).
The receiver operator characteristic comes for pro-
ductivity dementia bases on the CHA2DS2-VASc scores. 
CHA2DS2-VASc scores ≥ 4 identified by the ROC (sensiti-
vity 52.4%; specificity 73.0%, area under the cut-off AUC 
0.648) were associated with a higher rate of dementia. 
(Figure 2).
Table 2. Values of the logistic regression coefficient for the predictors of dementia analysed
Attribute (variable) Univariate analysis Multivariate analysis
b p value beta p value
Age 0.132 < 0.001 – –
   > 65 years 1.891 0.071 – –
   > 75 years 1.065 0.006 – –
Female sex 0.313 0.387 –0.225 0.599
City inhabitant 0.379 0.420 – –
Hypertension 0.560 0.293 – –
Diabetes mellitus –0.029 0.944 – –
Heart failure 0.786 0.033 – –
Ischaemic heart disease 0.813 0.078 – –
Hyperthyroidism 0.058 0.917 – –
Respiratory system diseases 0.465 0.430 – –
Prior vascular diseases (atherosclerosis) 0.470 0.256 – –
Rheumatic diseases 0.031 0.952 – –
Other diseases 0.766 0.036 – –
Duration of atrial fibrillation 0.272 0.209 0.242 0.318
Permanent atrial fibrillation 0.606 0.108 0.424 0.295
Anticoagulant treatment with NOAC 0.200 0.655 0.684 0.169
CHA2DS2-VASc score 0.386 0.003 0.385 0.003
NOAC — non-vitamin K oral anticoagulants




































Figure 1. Scatter diagram of Spearman’s rank correlation coeffi-
cient showing the relationship between the risk of thromboembolic 
complications measured by the CHA2DS2-VASc and the Mini-Men-
tal State Examination (MMSE) score
Discussion
It has been reported that AF may be associated with 
a higher risk of cognitive impairment. One important 
explanation is the increased incidence of stroke. AF is 
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a well — known risk factor of clinical and silent cerebral 
infarctions. It is not difficult to connect AF with post-stroke 
dementia. Multiple episodes of subclinical strokes may be 
a cause of CI [7, 8]. The authors’ interest is in the popu-
lation with AF without stroke or transient ischemic attack 
(TIA). What is the possible link between AF and dementia?
The subject literature offers information on cognitive 
impairment in patients with AF and a history of stroke, but 
there have been few studies on patients who did not suf-
fer a stroke. A correlation between AF and cognitive impair-
ment has been established, but more research is required 
to examine the exact mechanism of this relationship. Much 
controversy exists as to what factors mediate the deve-
lopment of CI or dementia in this group of patients [2, 3]. 
Several mechanisms have been proposed to explore the 
relationship between AF and CI or dementia. One possible 
explanation is the presence of other risk factors for demen-
tia such as age, hypertension, heart failure, diabetes mel-
litus, metabolic syndrome and hypercholesterolemia [9].
A meta-analysis conducted by Kalantarian et al. [2] 
summarizes data from prospective and non-prospective 
observational studies has suggested that AF is associated 
with a high risk of CI and dementia, with or without a hi-
story of clinical stroke.
Marzona et al. [3] conducted a post-hoc analysis of 
the trials ONTARGET and TRANSCEND that incorporated 
31 506 patients (1016 with AF at baseline) and proved that 
cognitive and functional decline are important consequen-
ces of AF, even in the absence of overt stroke. In a study 
by Farina et al. [10], which excluded patients with a history 
of stroke by detailed imaging, an association between AF 
and cognitive impairment was shown.
Forti et al. reported that AF was not significantly associa-
ted with dementia. In a population of patients with mild cog-
nitive impairment (MCI), atrial fibrillation was significantly 
associated with conversion to dementia [hazard ratio (HR): 
4.63; 95% confidence interval: 1.72–12.46], whilst no sig-
nificant association with AF was found in the group without 
cognitive impairment (HR: 1.10; 95% confidence interval: 
0.40–3.03). The authors concluded that atrial fibrillation 
may be a predictor of conversion to dementia in patients 
with MCI [11].
Our data also showed a significant correlation between 
AF and dementia in the non-stroke population (26.75% de-
mentia). It should be emphasised that all patients were ad-
ministered anticoagulant treatment. Recent publications 
suggest that warfarin use may reduce the incidence of de-
mentia in AF patients [12].
Our findings are consistent with those found in the 
available literature. Bellomo et al. [13] performed a deta-
iled geriatric assessment of two groups of ageing patients 
(mean age 71.76) with atrial fibrillation and normal sinus 
rhythm (control group) and demonstrated that patients 
with AF who completed the MMSE questionnaire more of-
ten obtained a score suggesting cognitive impairment than 
the controls (31% vs. 26%). It was also shown that AF may 
have an influence on the progression to dementia, even 
when a patient had no history of stroke [13].
We analysed cognitive function depending on the type 
of AF: paroxysmal, persistent or permanent. No differences 
were found with regard to the types of AF and their impact 
on the severity of cognitive impairment. The literature on 
the subject indicates there are no differences between tho-
se in complications such as stroke [14]. There are only se-
veral papers analysing dementia prevalence depending on 
AF type. The study by Knecht et al. [15] demonstrated a lack 
of any association between type of AF (paroxysmal/persi-
stent) and cognitive function. However, a downward trend 
in performance was observed in patients with chronic AF 
in tasks related to memorizing and learning (p = 0.0062).
Figure 2A, B. The receiver operator characteristic (ROC) curve, sensitivity and specificity of the test concerning the prevalence of dementia 
at CHA2DS2-VASc cut-off score > 4; AUC — area under the curve
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Therefore, it is very important to assess cognitive fun-
ction in patients with AF. This leads to the question of 
whether dementia in patients with AF is mediated through 
an increased risk of stroke or whether other factors are 
responsible. What could be the value of a CHA2DS2-VASc 
evaluation in predicting dementia? Which non-stroke pa-
tients with AF stroke should undergo an assessment of 
cognitive function?
There has been growing interest in the role of 
CHADS2 and CHA2DS2-VASc score in predicting cogniti-
ve impairment in patients with AF. However, the number 
of studies concerned with the relationship between the 
CHADS2 or CHA2DS2-VASc score and cognitive impairment 
is limited [16, 17].
In a population-based cohort study (Taiwan cohort) 
Chou et al. [16] investigated the correlation between the 
CHADS2 score and the future risk for vascular dementia or 
Alzheimer’s disease (mean follow up 3.71 ± 2.78 years, 38.2% 
with previous stroke/TIA) and showed that CHADS2 score is 
a useful predictor of the development of vascular dementia, 
as well as Alzheimer’s disease in patients with AF. Liao et 
al. in the study using the Taiwan AF cohort of 332 665 pa-
tients with AF (32.3% with the previous cerebral vascu-
lar incident and no history of dementia) showed that both 
CHADS2 and CHA2DS2-VASc scores were significant predictors 
of developing dementia during a 14-year follow-up in AF 
subjects. However, the CHA2DS2-VASc score was better than 
CHADS2 in predicting dementia [17].
In summary, the presented study shows a statistically 
significant correlation between the risk of thromboembo-
lic complications measured with the CHA2DS2-VASc scale 
and the score on the MMSE scale. The logistic regression 
analysis has shown that the CHA2DS2-VASc scale is an inde-
pendent and statistically significant determinant in patients 
with dementia, which correlates with the MMSE score.
Conclusion
The CHA2DS2-VASc score is a useful predictor of dementia. 
Patients with a CHA2DS2-VASc score > 4 are 1.5 times 
more likely to develop dementia than the population with 
a lower score.
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Streszczenie
Wstęp. Wiele badań wskazuje na związek między migotaniem przedsionków (AF) a zwiększonym ryzykiem pogorszenia 
się funkcji poznawczych. Nie wiadomo, czy skala CHA2DS2-VASc pozwala na przewidywanie rozwoju demencji u pacjen-
tów z AF.
Celem było wskazanie, czy wynik w CHA2DS2-VASc może być predyktorem demencji ocenianej za pomocą kwestionariu-
sza Mini-Mental State Examination (MMSE) wśród chorych z AF w podeszłym wieku.
Materiał i metody. Badaniem objęto 157 pacjentów (średnia wieku 73,4 roku) z niezastawkowym AF bez historii udaru 
mózgu w wywiadzie. Obecność demencji zdefiniowano jako wynik w MMSE mniejszy lub równy 23 punktom.
Wyniki. Analiza jednoczynnikowa wykazała, że wiek (b = 0,132; p < 0,001), niewydolność serca (b = 0,786; p = 0,033) 
oraz wynik w CHA2DS2-VASc były istotnymi determinantami demencji. W analizie wieloczynnikowej wynik w skali CHA2DS2-
-VASc okazał się niezależnym predyktorem demencji (β = 0,385; p = 0,003). Częstość występowania demencji była 
półtora razy większa w grupie chorych z wynikiem w CHA2DS2-VASc przekraczającym 4 punkty (iloraz szans = 0,47) niż 
w grupie chorych z wynikiem w CHA2DS2-VASc mniejszym lub równym 4 punktom.
Wniosek. Skala CHA2DS2-VASc jest przydatnym narzędziem predykcyjnym demencji w starzejącej się populacji z AF bez 
historii udaru mózgu.
Słowa kluczowe: migotanie przedsionków, funkcje poznawcze, upośledzenie funkcji poznawczych
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